Literature DB >> 10380937

Expression of cell cycle regulators in human cutaneous malignant melanoma.

L Tang1, G Li, V A Tron, M J Trotter, V C Ho.   

Abstract

We postulate that genes involved in the control of cell proliferation are important determinants of melanoma growth and/or transformation. Using Western blot analysis, we compared the expression of nine key cell cycle regulators in metastatic melanomas with that in benign acquired naevi. Among the cyclin-dependent kinases (CDKs) examined, CDK2 was consistently and significantly overexpressed (three- to eight-fold) in metastatic melanomas compared with naevi. CDK1 and CDK4 exhibited no significant difference in expression between benign naevi and metastatic melanomas. CDK6 expression was variable, with four out of 10 metastatic melanomas showing higher expression than naevi. All the cyclins examined, especially cyclins A and D, were expressed more in metastatic melanomas than in naevi. Cyclin E was not detected in benign naevi, but was easily detectable in most of the metastatic melanomas. In addition, there was significantly greater expression of CDC25A, a tyrosine phosphatase that activates CDK kinases, in the metastatic melanomas. Over-expression of CDK2, CDK6, CDC25A and cyclin A was confirmed in melanoma cell lines. These cell cycle regulators may play an important role in melanoma growth and/or transformation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10380937     DOI: 10.1097/00008390-199904000-00006

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  11 in total

1.  Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions.

Authors:  J Georgieva; P Sinha; D Schadendorf
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

2.  Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model.

Authors:  Karuppiah Kannan; Norman E Sharpless; Jin Xu; Ronan C O'Hagan; Marcus Bosenberg; Lynda Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

3.  Family history of melanoma and Parkinson disease risk.

Authors:  X Gao; K C Simon; J Han; M A Schwarzschild; A Ascherio
Journal:  Neurology       Date:  2009-10-20       Impact factor: 9.910

Review 4.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

5.  Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.

Authors:  Susan Burdette-Radoux; Richard G Tozer; Reinhard C Lohmann; Ian Quirt; D Scott Ernst; Wendy Walsh; Nancy Wainman; A Dimitrios Colevas; Elizabeth A Eisenhauer
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

6.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.

Authors:  Soledad R Alonso; Pablo Ortiz; Marina Pollán; Beatriz Pérez-Gómez; Lydia Sánchez; Ma Jesús Acuña; Raquel Pajares; Francisco J Martínez-Tello; Carlos M Hortelano; Miguel A Piris; José L Rodríguez-Peralto
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 7.  Cell cyclins: triggering elements of cancer or not?

Authors:  Michael Stamatakos; Victoria Palla; Ioannis Karaiskos; Konstantinos Xiromeritis; Ioannis Alexiou; Ioannis Pateras; Konstantinos Kontzoglou
Journal:  World J Surg Oncol       Date:  2010-12-22       Impact factor: 2.754

Review 8.  Cancer and neurodegeneration: between the devil and the deep blue sea.

Authors:  Hélène Plun-Favreau; Patrick A Lewis; John Hardy; L Miguel Martins; Nicholas W Wood
Journal:  PLoS Genet       Date:  2010-12-23       Impact factor: 5.917

9.  MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets.

Authors:  Feng Dong; Dinghua Lou
Journal:  Mol Vis       Date:  2012-03-01       Impact factor: 2.367

10.  Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.

Authors:  Alessandra Capasso; Carmen Cerchia; Carmen Di Giovanni; Giuseppina Granato; Francesco Albano; Simona Romano; Emmanuele De Vendittis; Maria Rosaria Ruocco; Antonio Lavecchia
Journal:  Oncotarget       Date:  2015-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.